Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097990 | 0.88 | ALDH1A1 (0.47) | ALDH1A1KDM4EPAOXUSP2HPGD | |
| SCHEMBL2512123 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4EPAOXUSP2HPGD | |
| SCHEMBL8865 | 0.83 | PAOX (0.52) | ALDH1A1PAOXUSP2HPGDHRH3 | |
| SCHEMBL23471288 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EPAOXUSP2HPGD | |
| SCHEMBL21907048 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EPAOXUSP2HPGD | |
| SCHEMBL20325468 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KDM4EPAOXUSP2HPGD | |
| SCHEMBL4902016 | 0.82 | GNAI3 (0.47) | ALDH1A1KDM4EUSP2HPGDHRH3 | |
| SCHEMBL9367 | 0.81 | PAOX (0.55) | ALDH1A1PAOXUSP2HPGDHRH3 | |
| SCHEMBL23471047 | 0.80 | GNAI3 (0.50) | ALDH1A1KDM4EUSP2HPGDRAB9A | |
| SCHEMBL20234243 | 0.80 | ALDH1A1 (0.45) | ALDH1A1KDM4EPAOXUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060148819-A1 | Chemical compounds | HENNEQUIN LAURENT F A | 2006-07-06 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-6887874-B2 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| US-20030212055-A1 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| US-20030207878-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | ALDH1A1 1187/4885KDM4E 1951/4885PAOX 4423/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | ALDH1A1 822/4885KDM4E 2055/4885PAOX 4236/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | ALDH1A1 2513/4885KDM4E 2595/4885PAOX 4194/4885 |
| US-20060148819-A1 | Chemical compounds | VEGFA, NOS3, FLT4 | ALDH1A1 1051/4885KDM4E 3568/4885PAOX 3172/4885 |
| US-20030207878-A1 | Chemical compounds | CYP3A7, HTR3C, CNR1 | ALDH1A1 1354/4885KDM4E 3367/4885PAOX 2242/4885 |
| US-20030212055-A1 | Cinnoline compounds | VEGFA, PGF, CCR7 | ALDH1A1 335/4885KDM4E 2566/4885PAOX 3997/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | ALDH1A1 3323/4885KDM4E 1506/4885PAOX 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.